Requesting Abstracts from:
- Young Investigator
- General Attendee
Young Investigator & Trainee Abstract Submissions
The Joint International Oncology (Sentinel Node and Cancer Metastasis) Congress will feature an ongoing exhibition of posters submitted by Young Investigators (age under 45) and Trainees (including Residents, Fellows and Students).
Abstract submissions will be judged by a Young Investigator/Trainee Task Force for acceptability and award-worthiness.
The top three of the abstracts submitted by Young Investigators and top three by Trainees (includes Residents, Fellows, and Students) will be honored with cash awards presented during a Wine and Cheese Reception. Winning authors of these abstracts will be asked to deliver brief (5-minute) presentations about their topics at this time.
General Attendee Abstract Submissions
The Joint International Oncology (Sentinel Node and Cancer Metastasis) Organizing Committee also invites Abstract Submissions from general attendees. General attendees include investigators older than 45 years of age who are not trainees, residents, fellows or students. The organizing committee will review all the abstracts and the top 30% will be selected for oral presentations.
Decision on Abstracts
The organizing committee will review all the abstracts and the top 30% of all abstracts from Young Investigator, Trainee and General Attendee categories will be selected for oral presentations. All accepted abstracts will be presented as posters (48″ x 48″).
INSTRUCTIONS FOR ABSTRACT SUBMISSIONS
Deadline: February 28, 2013
The Young Investigator/Trainee Abstract Task Force and the Joint International Oncology (Sentinel Node and Cancer Metastasis) Organizing Committee remind the attendees that the material deemed appropriate for presentation at the symposium should have the following characteristics:
- Original and new scientific work
- Abstracts should be on either basic scientific or clinical subject matter related to the general Symposium agenda topics and pertain to cancer metastasis
- The submitted abstract should not be related to work submitted to, or being considered by other organizations and/or journals
Abstracts submitted must adhere to the following specifications to be considered for presentation at the 2012 Joint International Oncology (Sentinel Node and Cancer Metastasis):
- Abstracts must be authored, co-authored and must be limited to 300 words under the headings of background/hypothesis; materials and methods; results; and conclusions
- Title, authors and institutions are excluded in the 300 word limit
- Abstracts should be in English
- Abstracts must be formatted as a Microsoft Word document and be single-spaced
- Font: Arial size 12
- Margins: 1 inch on all sides
Please indicate whether the first author is:
- A Young investigator (under 45 years of age)
- A Trainee (Resident/Fellow/Student)
- or NOT a Young Investigator or Trainee (Resident/Fellow/Student)
- Title should be flush with margin at the top left hand corner of the box. End title with a period
- Use no abbreviations in title
- Do not use capital letters in title except for words that are always capitalized
Authors & Institutions
- Group authors together—last name followed by first initial and middle initial. Omit academic degrees and titles. End list of authors with a period
- Group institutions together, and provide institution names, cities, states/provinces. Show countries last, if not US. End list of institutions with a period
- For cooperative study groups, it is permissible to give the name of the group instead of individual institutional affiliations.
The content of the abstract should include the following:
- Background/Hypothesis or Background/Objective
- Materials and Methods
CONTENT FOCUS: Abstract should describe research objectives and rationale, as well as specific results. Content should reflect either basic scientific or clinical subject matter related to any of the general Joint International Oncology (Sentinel Node and Cancer Metastasis) agenda topics and pertain to cancer metastasis. See sample abstract below.
Please email your abstract submission as an attachment in a Microsoft Word document to:
Format the subject line of your email as follows:
Subject: Young Investigator or Trainee Abstract Submission or General Attendee Abstract Submission
In your email message, PLEASE INDICATE WHETHER THE FIRST AUTHOR IS A YOUNG INVESTIGATOR, TRAINEE, FELLOW OR RESIDENT or A GENERAL ATTENDEE of the Congress.
Please identify your abstract in the following categories:
- Breast Cancer
- GI Cancer
- Other Cancer
- Cancer Metastasis
Confirmation of Receipt
You will receive a confirmation email that your abstract has been received.
Only electronically submitted abstracts are accepted.
Abstract Acceptance and Poster Guidelines
Decision letters, along with presentation instructions, will be emailed to the presenter by May 1, 2013.
- Chosen abstracts will be presented and honored in a poster/oral sessions.
- Awards of $1,500 each will be presented for the three best Young Investigator and three best Trainee abstracts. (General Attendee abstracts carry no cash award)
- Finished posters must be no larger than 48″ x 48″ for presentation
Abstract Acceptance and Oral Presentation Guidelines
The top 30% of all accepted abstracts will be invited for oral presentations. The first author will be the presenter, who has 7 min to present the abstract in power points and 3 min for Q&A. Additional guidelines will be sent to each presenter.
PLEASE NOTE: SUBMITTING AN ABSTRACT DOES NOT CONSTITUTE REGISTRATION FOR THE CONGRESS.
The first author or the presenter must register to attend the Congress. All future correspondence from the Congress will be emailed to The First Author (Presenter).
|Abstract title at top left hand corner of the box, flush with top left margin. Title is in bold face and should end with a period.||Telomerase is a prognostic marker in breast cancer: high-throughput tissue microarray analysis of hTERT and hTR expression.
Poremba C, Diallo R, Heine B, Sauter G, Boecker W. Westfaelische-Wilhelms University, Muenster, Germany; Free University, Berlin, Germany; University of Basel, Basel, Switzerland.
Background/Hypothesis: Telomerase activity (TA) has been shown to correlate with poor clinical outcome in neuroblastomas, gastric cancer, and others, indicating that tumors expressing this enzyme may be more aggressive and that TA may be a useful prognostic marker. For breast cancer, however, there is controversy with respect to TA as a prognostic marker; whereas some studies suggest an association between TA and disease outcome, others do not find this association.
Material and Methods: Using tissue microarrays (breast carcinoma prognosis arrays) containing 611 samples (diameter 0.6 mm each) from the tumor center of paraffin-embedded breast carcinomas, we analyzed the catalytic subunit of telomerase, human telomerase reverse-transcriptase (hTERT), and the internal RNA component (hTR), which are the core components of the telomerase holoenzyme complex. hTERT protein expression was obtained by immunohistochemistry (human anti-telomerase antibody Ab-2, Calbiochem), and hTR RNA was measured by radioactive in-situ hybridization. hTERT and hTR were determined semiquantitatively (scores 1-4). Clinical data, such as histologic subtype, pT-stage, tumor diameter, pN-stage, BRE-grade, tumor specific survival (in months), patient’s age, and others, were available for statistical analysis.
Results: We found a statistically significant correlation between tumor specific survival (over survival) and hTERT expression (p<0.0001) or hTR expression (p=0.00110). Tumors with higher scores (scores 3, 4) for hTR and/or hTERT were associated with a worse prognosis. Ongoing studies are evaluating whether or not hTERT, hTR or both are independent prognostic factors.
Conclusion/Discussion: Previous studies, focusing on analysis of TA in smaller numbers of fresh-frozen breast carcinomas by the TRAP assay, revealed controversial results with respect to TA as a prognostic marker in breast cancer. Using tissue microarrays from 611 breast carcinomas, we demonstrated that increased expression levels of the telomerase core components, hTERT and hTR, are associated with lower overall survival. These findings suggest that TA as a prognostic marker in breast cancer should be included in future validation studies.
|Capitalizationshould be used only for words that are always capitalized.|
|Group authors together, with last name followed by first initial and middle initial. End authors’ listing with a period.|
|Group institutions together, and include institution names, cities, states/provinces. Show country if not US. End listing of institutions with a period.|
|For cooperative study groupsyou may give the name of the group instead of individual institutional affiliations.|